Нейротропная активность потенциального нейролептика N-капроил-пролил-трозина
Диссертация
Начало изучения нейролептиков (антипсихотических веществ) восходит к 1952 году, когда впервые был успешно применен для лечения душевных заболеваний аминазин (хлорпромазин). С этого открытия началась разработка «типичных нейролептиков», основной характеристикой действия которых являются, наряду с антипсихотическим действием, выраженные побочные эффекты (экстрапирамидные нарушения, тардивная… Читать ещё >
Список литературы
- Авруцкий Г. Я., Недува А. А. Лечение психических больных. М., Медицина, 1988.
- Азарашвили A.A. Исследование механизмов памяти с помощью физиологически активных соединений. М.Наука. 1981. — 188с.
- Архипов В. И. Азарашвили A.A. О механизмах возникновения диссоциированных состояний мозга. // Успехи физиолог, наук. 1989. — № 2. — С.63−71.
- Барков Н. К. К вопросу о механизме действия карбидина. // Фармакол. токсикол. -1973. -Т. 36. -N. 2. -с. 154−157.
- Бондаренко Н. А. Избирательное влияние нейролептиков на дофамино-зависимое нарушение поведения крыс в тесте экстраполяционного. избавления //Бюлл. эксперим. биол. и мед. -1990. -Т. 110. N. 11. -с. 506−508.
- Гарибова Т.Л., Воронина Т. А., Стефанков Д. В., Калинина Т. С. Оценка действия фармакологических средств на основе новой компьютерной программы для анализа оперантного поведения животных. // Фарм. и токсиколог. 1990. — № 1. -С. 67−70.
- Гудашева Т.А. Новая сиратегия пептидного дизайна на примере создания оригинальных ноотропов и нейролептиков. // Автореферат на соискание д.б.н., Москва, 1998.
- Гудашева Т.А., Зайцева Н. И., Бондаренко H.A., Щербакова И. Э., Асмакова Л. С., Розанцев Г. Г., Островская Р. У., Воронина Т. А., Серединин С. Б. Дизайн, синтез и нейролептическая активность дипептидных аналогов сулышрида. // Хим. Фарм. Ж. -1997.-№ 11,С.10−16.
- Жарковский А. М., Классен H. Е., Жарковская Т. А. Влияние карбидина на дофаминовые и серотониновые рецепторы центральной нервной системы. // Бюлл. экспер. биол. мед. -1985. -N. 6. -с. 700−702.
- Ю.Жарковский A.M. (под ред.) Экспериментальное доклиническое изучение специфической активности новых соединений, предлагаемых для клинических испытаний в качестве нейролептиков (антипсихотических средств). Методические рекомендации // Москва, 1988.
- З.Калинин В. В. Влияние нейролептиков, мидантана и ДОФА на апоморфиновую стереотипию у крыс. // Фармакол. токсикол. -1977. -Т.40. -N.I.-C.16−19.
- Кругликов Р.И. Нейрохимические механизмы обучения и памяти. // М., «Наука». -1981.
- Кудрин B.C., Хетеи JL, Моргенштерн Р., Раевский К. С., Ольснер В. Влияние атипичных нейролептиков карбидина и сульпирида на биосинтез дофамина в синаптосомах прилежащего ядра крыс. И Фармакол. токсикол,-1987. N.2. -с. 16−19.
- Парин В. В. Влияние карбидина на продолжительность и силу действия наркотических веществ. // Фармакол. токсикол. -1973. -Т. 36. -N. 2.-е. 157−161.
- Раевский К.С. Фармакология нейролептиков"). // Москва, Медицина -1976,272с.
- Abi-Saab W.M., D’Souza D.C., Moghaddam В., Kiystal J.H. The NMDA antagonist model for schizophrenia: promise and pitfalls. // Pharmacopsychiatry. 1998. -Vol.31. -Suppl.2.-P. 104−109.
- Ader R., Weijnen J.A.W.M., Moleman P. Retention of a passive avoidance response as a function of the intensity and duration of electric shok. // Psychol. Sci. 1972. -Vol.26. -N3. — P. 125−128.
- Alander Т., Anden M. E., Grabowska-Anden M. Metoclopramide and sulpiride as selective blocking agents of pre- and postsynaptic dopamine receptors. // Arch. Pharmacol. -I980.-Vol. 312. -P. 145−150.
- Anden N.E., Butcher S.G., Corrodi H., Fuxe K., Ungerstedt U. Recetor activity and turnover of dopamine and noradrenaline after neuroleptics. // Eur. J. Pharmacol. -1970. Vol. 11. — P.303−314.
- Angrist B, Sathananthan G., Wilk S., Gershon S. Amphetamine psychosis: behavioral and biochemical aspects. // J.Psychiatr. Res. 1974. — Vol. 11. — P. 13−23.
- Angulo J.A., McEwen B.S. Molecular aspects of neuropeptide regulation and function in the corpus striatum and nucleus accumbens. // Brain Res. Reviews. 1994. -Vol. 19. — P. 1−28.
- Arnt J. Hyperactivity induced by stimulation of separate dopamine D-l and D-2 receptors in rats with bilateral 6-OHDA lesions. // Life Sci. -1985. -Vol. 37. -N. 8. -P. 717 723.
- Babiy III H., Steenberg M. L., Manian A. A. Buckley J. P. Effects of chlorpromazine and three metabolites on behavioral responses in rats. // Psy-chopharmacologia (Beri). 1974. — Vol.34. — P.351−360.
- Baldessarini RJ., Frankenburg F. R. CLOZAPINE A Novel Antipsychotic Agent. //New England Journal of Medicine. -1991. -Vol. 324.-P. 746−754.
- Bartholini G. Differential effect of neuroleptic drugs on dopamine turnover in extrapyramidal and limbic system. // J.Pharm.Pharmacol. 1976. — Vol.28. — P.429−433.
- Bartholini G., Haefely W., Jalfre M., Keller H. H., Pletscher A. Effects of clozapine on cerebral catechoiaminergic neurone systems. // Brit. J. Pharmacol. -1972. -Vol. 46. -P. 736−740.
- Berry S.J.L., Gudelsky G.J.L. Evidence for protein kinase-C mediation of the neurotensin-induced activation of tyrosine hydroxylase in tuberoinfundibular dopaminergic neurons. //Endocrinology. 1992. — Vol.131. — P. 1207−1211.
- Bissette G., Dauer W.T., Kilts C.D., O’Connor L., and Nemeroff C.B. The effect of stereoisomers of butaclamol on neurotensin concentrations in discrete regions of the rat brain. //Neuropsychopharmacology. 1988. — Vol. 1. — P.329−335.
- Bissette G., Nemeroff C. B The neurobiology of neurotensin. // American College of Neuropsychopharmacology’s Fourth Generation of Progress. Raven Press. -1994.
- Blumstein L. K., Crawley J.N., Davis L.G., Baldano F.Jr. Neuropeptide modulation of apomorphine-induced stereotype behavior. // Brain Res. 1987. — Vol. 404(1−2). -P.293−300.
- Boissier J.R., Simon P. L’utilisation du test de la traction test de (Julou-Courvuisier) pour l’etude des psycholeptiques. // Therapie. 1960. — Vol. 15. — N.6. -P. 1170−1174.
- Borison R. L, Diamond B. L. Regional selectivity of neuroleptic drugs: an argument for site specificity. // Brain Res. Bull.-1983. -Vol. 11. -P. 215−218.
- Brady J.V., Nauta W.J. Subcortical mechanisms in emotional behavioral affective changes following septal forebrain lessions in the albino rat. // J. Compar. Physiol. Psychol. 1953. — Vol.46. — N3. — P.339−341.
- Bristow L.J., Kramer M.S., Kulagowski J., Patel S., Ragan C.I., Seabrook G.R. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. // Trends Pharmacol. Sci. 1997b. — Vol. 18(6). -P. 186−188.
- Burki H. R. Effects of fluperlapine on dopaminergic systems in rat brain. //Psychopharmacology-1986. -Vol. 89. -P. 77−84.
- Cadet J.L., Kayoko K., Carlson E., Epstein, C.J. Autoradiographic distribution of 3H. neurotensin receptors in the brains of superoxide dismutase transgenic mice. // Synapse. 1993. — Vol.14. — P.24−33.
- Cadet J.L., Kayoko K, Przedborski S. Bilateral modulation fH. neurotensin binding by unilateral intrastriatal 6-hydroxydopamine injections: evidence from a receptor autoradiographic study. //Brain Research. -1991. Vol.564. — P.37−44.
- Caley C.F., Weber S.S. Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. // Ann. Pharmacotherapy. 1995. — Vol.29. — P.152−159.
- Canini F., Bourdon L. Dopamine involvement in thermoregulatory responses to heat in rats. // Neurosci Lett. 1998. — Vol.241(2−3). — P.91−4
- Carlsson A., Hansson L.O., Waters N., Carlsson M.L. Neurotransmitter aberrations in schizophrenia: new erspectives and therapeutic implications. //Life Sci. -1997. Vol.61. -P.75−94.
- Carlsson M., Carlsson A. Interaction between glutamatergic and monoaminergic systems within the basal ganglia: implications for schizophrenia and Parkinson’s disease. // Trends Neurosci. 1990. — Vol. 13. — P.272−276.
- Carraway R. E., and Leeman S. E. Peptides: Chemistry, Structure and Biology /R. Walter and J. Meienhofer, eds. Ann Arbor Science, Ann Arbor. — 1975. -P. 679−685.
- Castel M.N., Wang WJL, Laduron P.M., Beaudett A. Light and electron microscopic localization of retrogradely transported neurotensin in rat nigrostriatal dopaminergic neuroris. //Neuroscience. 1992. — Vol.50. — P.269−282.
- Chabry J., Gaudriault G., Vincent J.P., Mazella, J. Implication of various forms of neurotensin receptors in the mechanism of internalization of neurotensin in cerebral neuroris. //J. Biol. Chem. 1993. — Vol.268. — P. 17 138−17 144.
- Chakravarty P.K., Edison N.J., Richard W.R. Substituted triazolinones, triazolinethiones, and triazohnimines as neurotensin antagonists used to treat psychosis. // US 5 250 558 1993.
- Chandra A., Chou H. C., Lin M. T. Effects of intraventricular administration of neurotensin and somatostatin on thermoregulation in the rats.// Newopharmacology. -1981. Vol.20(7). — P.715−718.
- Chang W. H., Chen T. Y., Yeh B. K. Time-response curves of homovanilic acid in caudate and pre- frontal cortex following acute neuroleptic administration. // Psychopharmacology. -1978. -Vol. 93. -P. 403−404.
- Chernov H. I., Wilson D.E., Fowler W.F., Plummer A.J. Non-specificity of the mouse writhing test. //Arch. Int. Pharmacodyn. Ther. 1967. — Vol. 167(1). — P. 171−178.
- Chiodo L.A., Bunney B.S. Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. // J.Neurosci. 1983. — Vol.3. — P. 1607−1619.
- Clark D., White F. J. Review: D1 dopamine receptor the search for a function- a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. // Synapse -1987. -Vol. l.-P. 347−388.
- Clineschmidt B. U.7 McGuffin J. C., and Bunting P. B. Neurotensin antinocisponsive action in rodents. // Eur. J. Pharmacol. -1979. Vol.54. — P. 129−139.
- Code R. A., Tang A. H. Yawning produced by dopamine agonists in rhesus monkeys. //Eur. J. Pharmacol. -1991. -Vol. 201. -N. 2−3.-P. 235−238.
- Coffin V.L., Latranyi M.B., Chipkin R.E. Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors. // J. Pharmacol. Exp. Ther. 1989. — Vol. 249, N 3. — P. 69−775.
- Cohen C., Sanger D.J., Perrault G. Characterization of the discriminantive stimulus produced by the dopamine antagonist tiapride. // J. Pharmacol. Exp. Ther. 1997. -Vol.283. — N2.-P.566−573.
- Colpaert F. C., Niemegeers C. J. E., Janssen P. A. J.: Theoretical and methodological considerations on drug discrimination learning. //Pychopharmacologia (Beri). 1976. — Vol.46. — P. 169−177.
- Contreras P.C., Quirion R., Gehlert D.R., Contreras M.L., O’Donohue T.L. Autoradiographic distribution of non-dopaminergic binding sites labeled byH.-haloperidol in rat brain. //Neurosci. Lett. 1987. — Vol. 75. — P. 133−140.
- Corbett R., Camacho F., Wood A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. // Psychopharmacology (Berl). 1995. — Vol.120. — P.67−74.
- Corbett R., Hartman H., Kerman L.L., Wood A.T., Strupczewski J.T., Helsley G.C., Conway P.C., Dunn R.W. Effects of atypical antipsychotic agents on social behavior in rodent. //Pharmacol. Biochem. Behav. 1993. — Vol.45. — P.9−17.
- Corne S.J., Pickering R.W., Warner B.T. A method for assessing the effects of drugs on the central actions of 5-hydroxythyphamine. // Br. J.Pharmacol. 1963. — Vol.20. -P. 106−120.
- Coward D. M., Imperato A., Urwyler S., White T. G. Biochemical and behavioral properties of clozapine. 11 Psychopharmacology. -1989.-Vol. 99. -P. S6-S12.
- Coyle J. T., Enna S. J. (Eds) Neuroleptics: neurochemical, behavioral and clinical perspectives. // New York. Raven press. -1983.
- D" Amor F.E., Smith D.L. A method for determining loss of pain sensation // J. Pharmacol. Exp. Ther. -1941. V.72. -Nl. — P.74−79.
- Davis A. S., Jenner P., Marsden C. D. Apomorphine induces grooming behaviour in rats pretreated with sulpride. // Brit. J. Pharmacol.-1985. -Vol. 86. Suppl. -P. 434.
- Deutsch S.I., Weizman E., Goldman M.E. Morihisa J.M. The sigma receptor: A novel site implicated in psychosis and antipsychotic drug efficacy. // Clin.Neuropharmacol. 1988.-Vol.11.-P. 105−119.
- Devaud L.L., Hollingsworth E.B., Cooper B.R. Alterations in extracellular and tissue levels of biogenic amines in rat brain induced by the serotonin (2) receptor antagonist, ritanserin. // J Neurochem. 1992. — Vol.59. — P. 1459−1466.
- Dewey S.L., Smith G.S., Logan J., et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. // J. Neurosci. 1995. — Vol.15. — P.821−829.
- Sl.Di Chiara G., Porceddu M.L., Vargiu L., Argiolas A., Gessa G.L. Evidence for dopamine receptors mediating sedation in the mouse brain. // Nature. 1976. — Vol.264. -P. 564−567.
- Dorsa D. M., De Kloet E. R., Mezey E., and De Wied D. Pituitary-brain transport of neurotensin: functional significance of retrograde transport. // Endocrinology. -1979. Vol. 104(6). — P. 1663−1666.
- Duinkerke S.J., Bolter P.A., Jansen A.A.I. et al. Ritanserin, a selective 5-HT (2/lc) antagonist, and negative symptoms in schizophrenia: a placebo-controlled double-blind trial. // Br J Psychiatry. 1993. — Vol. 163. — P.451−455.
- Dunham N.M., Miya T.S. A note on a simple apparatus for detecting neurological deficit in rats. // J.Am.Pharm.Ass. 1957. — Vol.46. — P.298−209.
- Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. // Brain Res. Rev. -1995. Vol.20(2). — P.250−267.
- Erwin V.G., Jones B.C. Genetic correlations among ethanol-related behaviors and neurotensin receptors in long sleep (LS) x short sleep (SS) recombinant inbred strains of mice. // Behavior Genetics. 1993. — Vol.23. — P. 191−196.
- Feifel D., Reza T.L., Wustrow D.J., Davis M.D. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. // J.Pharmacol. Exp. Ther. 1999. -Vol.288(2). — P.710−713.
- Fitton A., Heel R. C. Clozapine: A review of its Pharmacologycal Properties, and Therapeutic use in Schizophrenia. // Drug. -1990,-Vol. 40 (5). -P. 722−747.
- Freedman S. B., Peat J. A., Woodruff G. N. 3H-Sulpiride, a ligand for neuroleptic receptors. //Neuropharmacology. -1981. -Vol. 20. -P. 1323−1326.
- Frey P., Fuxe K., Eneroth P., Agnati L. F. Effects of acute and long-term treatment with neuroleptics on regional telencephalic neurotensin levels in the male rat. // Neurosci. Int. 1986. — Vol.8. -P.429−434.
- Glavin G.B., Hall A.M. Clozapine, a dopamine DA4 receptor antagonist, reduces gastric acid secretion and stress-induced gastric mucosal injury. // Life Sci. 1994. — Vol.54(16). — PL261−264.
- Goas J. A., Boston J. E.: Discriminative stimulus properties of clozapine and chlorpromazine. //Pharmac. Biochem. Behav. 1978. — Vol.8. — P. 235−241.
- Govoni S., Hong J.S., Yang H-Y.T., Costa E., Increase of neurotensin content elicited by neuroleptics in nucleus accumbens. // J. Pharmacol Exp. Ther. 1980. — Vol. 215. — P.413−417.
- Griffith J.D., Cavanaugh J., Held J., Oates J.A. Dextroamphetamine: evaluation of psychotomimetic properties in man. // Arch. Gen. Psychiatry. 1972. -Vol.26.-P.97−100.
- Groves P.M., Rebec G.V. Biochemistry and behavior: some central actions of amphetamine and antipsychotic drugs. // Ann. Rev. Psychol. 1976. — Vol.27. — P.91−127.
- Gui-Hua Cao., Woolverton W. L. Antagonism of guinpirole by (+) AJ-76 possible involvement of D3 receptors. //1991. -Vol. 209. N. 3. — P. 285−286.
- Gurevich E.V., Kung M.-P., Bordelon Y., Joyce J.N. Dopamine D3 receptors are elevated in mesolimbic dopamine system of schizophrenics- receptor autoradiographic studies. // Neuropsychopharmacology. 1994. — Vol. 10. — P.236S.
- Gyertyan I., Randy A. Comparison of effects of neuroleptic compaunds on spontoneous and conditioned behavior. // Eur. J. Pharmacol.-1990. -Vol. 183. -N.5. -P. 1893−1894.
- Haffher F. Experimental prufung Schmerzstillender mittel. // Dtsch. Med. Wschr. 1929. — Bd.55. — S731−733.
- Hart J.S. Rodents. In: Comparative physiology of the thermoregulation. Vol.2 New York: Academic Press- 1971,149p.
- Henry J.A., Horwell J.D.C., Meecham K.G., Rees J.D.C. A stmcture-affmity study of the amino acid side-chains in neurotensin: N and C terminal deletions and Ala-scan. 11 Bioorg. Med. Chem. Lett. 1993. — Vol.3. — P.949−952.
- Hietala J., Lappalainen J., Koulu M., Syvalanti E. Dopamine D1 receptor antagonism in schizophrenia: is there reduced risk of extrapyramidal side-effects. 11 Trends Pharmacol. Sci. 1990. — Vol. 11. — N 10, P. 408−410.
- Honda F., Satoh Y., Shimomura K., Satoh H., Noguchi H., Uchida S., and Katol R. Dopamine receptor blocking activity of sulpiride in the central nervous system. 11 Jpn. J. Pharmacol. 1977. — Vol.27(3). — P.397−411.
- Psychiat. and Neurol.-1991. -Vol. 45. -N. 3. -P. 723−733.
- Imperato A., Angelucci L. The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the prefrontal cortex of freely moving rats. // Psychopharmacol. Bull -1989. -Vol. 25. -P. 383−389.
- Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. //Am.J.Psychiatry. -1991. Vol.148. — P.1301−1308.
- Johnson S.J., Akunne H.C., Heffiier J.G., Kesten S.R., Pugsley T.A., Wise L.D., Wustrow D.J. Novel small molecule neurotensin antagonists: 3-(l, 5-diaryl-l, 5-dioxopentan-3-yl)benzoic acids. // Bioorg. Med. Chem. Lett. 1997. -Vol.7(5). — P.561−566.
- Johnson S.J., Kesten S.R., Wise L.D., Wustrow D.J. Neurotensin antagonists. // US 5 430 047 1995.
- Jolicoeur F. B., Barbeau A., Rioux F., Quirion R., and St-Pieire S. // Differential neurobehavioral effects of neurotensin and structual analogues. // Peptides. -1981. Vol.2.-P.171−175.
- Jolicoeur F. B., De Michele G., Barbeau A., and St-Pierre S., Neurotensin affects hyperactivity but not stereotypy induced by pre and post synaptic dopaminergic stimulation. //Neurosci. Biobehav. Rev. 1983. Vol. 7. — P.385−390.
- Jolicoeur F.B., Gagne M.A., Rivest R., Drumheller A., St-Pierre S., Atypical neuroleptic-like behavioral effects of neurotensin. // Brain Research Bulletin. 1993. -Vol.32. -P.487−491.
- Jolicoeur F.B., Rioux F., St.-Pierre S. Neurotensin. // Handbook Neurochemictry. 1985. — N8. — P93−113.
- Jolicoeur FB, Gagne MA, Rivest R, Drumheller A, St-Pierre S. Neurotensin selectively antagonizes apomorphine-induced stereotyped climbing.// Pharmacol. Biochem. Behav. -1991. Vol.38(2). — P.463−465.
- Jondie A.J., Smith J.A., Robertson A., Cavanagh C. Clozapine as a drug of dependence. //Psychopharmacology. 1999. — Vol.142. — P.369−374.
- Kalivas P. W., Jennes L., Nemeroff C. B. and Prange A. J., Jr. Neurotensin: topographical distribution of brain sites involved in hypothermia and antinociception. // J. Comp. Neurol. 1982. — Vol.210. — P.225−238.
- Kalivas P.W., Miller J.S. Neurotensin neurons in the ventral tegmental area project to the medial nucleus accumbens. // Brain Res. 1984. Vol.300. — P. 157−160.
- Kalkman H.O., Neumann V., Hoyer D., Tricklebank M.D. The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat. // Br. J. Pharmacol. 1998. — Vol. 124(7). — P. 1550−1556.
- Kawashima K., Araki H., Aihara H. Effect of chronic administration of antidepressants on duration of immobility in rats forced to swim. // Jpn. J. Pharmacol. -1986. Vol.40(2). — P. 199−204.
- Kelly P.H., Iversen S.D. Selective 6-OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. // Eur.J.Pharmacol. -1976. Vol.40. — P.45−56.
- Kilts, C.D., Anderson, C.M., Bissette, G., Ely, T.D., and Nemeroff C.B. Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei. // Biochem. Pharmacol. 1988. — Vol.37. — P. 1547−1554.
- Knoll J., Motimeter, a new sensitive apparatus for the quantitative measurement of hypermotility caused by psychostimulants. // Arch. Int. Pharmacodyn. -1961, — Vol.130. P. 141−154.
- Koob G.F., Le H.T., Creese I. D1 receptor antagonist SCH 23 390 increases cocaine self-administration in the rat. //Neurosci. Lett. 1987. — Vol. 79.-.P.315−320.
- Koshikawa N., Mori E., Maruyama Y., Yatsushige N., Kobayashi M. Role of dopamine D-l and D-2 receptors in the ventral striatum in the turning behaviour of rats. // Eur. J. Pharmacol. -1990. -Vol. 178.-N. 2. -P. 233−237.
- Kovacic B., Ruffing D., Stanley M. Effect of neuroleptics and of potential new antipsychotic agents (MJ 13 859-L and MJ 13 980-L) on a monkey model of tardive dyskinesia. // Journal of Neural Transmission.-1986. -Vol. 65. -P. 39−49.
- Kullingsjo H., Carlsson A., Svensson K. Effects of repeated administration of the preferential dopamine autoreceptor antagonist, (+) -AJ-76, on locomotor activity and brain DA metabolism in the rat. //Eur. J. Pharmacol. -1991. -Vol. 205. -P. 241−246.
- Lahti R.A., Roberts R.C., Conley R.R., Cochrane E.V., Mutin A., Tamminga C.A. D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. // Neuroreport. 1996. — Vol.7. — P. 1945−1948.
- Levant B. and Nemeroff C.B. Further studies on the modulation of regional brain neurotensin concentrations by antipsychotic drugs: Focus on haloperidol and BMY 14 802. // J.Pharmacol. Exp. Ther. 1992. — Vol.262. — P.348−355.
- Levant B., Bissette G., Wideriov E., Nemeroff C.B. Alterations in regional brain neurotensin concentrations produced by atypical antipsychotic drugs. // Reg. Peptides. -1991. Vol.32. — P. 193−201.
- Levant B., NemerofF C.B. The psychobiology of neurotensin // In Ganten D, Pfaff D, eds. / The Neuroendocrinology of mood. 1988. — Vol. 8. — Springer, Berlin. — P. 231−262.
- Levante B., Nemeroff C.B. Sigma receptor «Antagonist» BMY 14 802 increases neurotensin concentrations in the rat nucleus accumbens and caudate. // J. Pharm. Exp. Ther. 1990. — Vol.254. — N1. — P.330−335.
- Lin M.T., Ho M.T., Young M.S. Stimulation of the nigrostriatal dopamine system inhibits both heat production and heat loss mechanisms in rats. // Naunyn-Schmiedeberg's Arch. Pharmacol. 1992. — Vol.346(5). — P.504−510.
- Lin M.T., Wang H.S., Wang Z., Chern Y.F. Haloperidol produces hypothermic effects in rats. //Experientia. 1979. — Vol.35(ll). — P. 1469−1470.
- Lindefors N., Sharp T., Ungerstedt U. Effects of subchronic haloperidol and suipiride on regional brain dopamine metabolism in the rat. // Eur. J. Pharmacol. -1986. -Vol. 129. -P. 401−404.
- Lindstrom L. H, Wideriov E., Bissette G., Nemeroff C.B. Reduced CSF neurotensin concentration in drug-free schizophrenic patients. // Schizophrenia Res. -1988.-Vol.1.-P. 55−59.
- Lister R.G. The use of a plus-maze to measure anxiety in the mouse. // Psychopharmacol. 1987. — Vol.92. — P. 180−185.
- Ljungberg T., Ungerstedt U. Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanisms of action. //Psychopharmacology. -1978. -Vol. 56. -P. 239−247.
- Luby E.D., Cohen B.D., Rosenbaum F., Gottlieb J., Kelley R. Study of a new schizophrenomimetic drug. // Sernyl. Arch. Neurol. Psychiatry. 1959. — Vol.81. — P. 363 369.
- Luttinger D., King R. A., Sheppard D., Strupp J., Nemeroff C. B., and Prange A. J., Jr. The effect of neurotensin on food consumption in the rat. // Eur. J. Pharmacol. -1982a. Vol.81(3). — P.499−503.
- Luttinger D., NemerofF C. B., and Prange A. J., Jr. The effect of neurotensin on discrete-trial conditioned avoidance responding. // Brain Res. 1982b. — Vol.237(1). — P. 8382.
- Mackintosh N.J. Approaches to the study of animal intelligence. // Brit. J. Psychol. 1988. — Vol.79. -P.509−515.
- Mafirand J.-P., Gully D., Boigegrain R., Jeanjean F. New potent and selective non-peptide antagonistas of neurotensin receptors. // Eur. J. Med. Chem. 1995. — Vol.30 (Suppl.l). — S551-S573.
- Mailman R.B., Schulz D.W., Lewis M.H., Staples L., Rollema H., Dehaven D.L. SCH 23 390: A selective D1 dopamine antagonist with potent D2 behavioral actions. Eur.J.Pharmacol. 1984. — Vol.101. — P. 159−160.
- Makanjuola R.O.A., Hill G., Dow C., Campbell G., Asshcroft G.W. The effects of psychotropic drugs on exploratory and stereotyped behaviour of rats studied on a Hole-Board // Psychopharmacol. -1977. Vol.55. — P.67−74.
- Maldonado R., Baamonde A., Dauge V., Feger J. Effects induced by chronic treatment with selective Dl, or D2 antagonist on open-field behavior and colonic temperature. //Fundam. and Clin. Pharmacol.-1990. -Vol. 4. -N. 3. -P. 341−356.
- Malhotra A.K. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. // Neuropsychopharm. 1996. — Vol. 14(5). — P.301−307.
- Malhotra A.K., Pinals D.A., Adler C.M., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. //Neuropsychopharmacol. 1997. — Vol.17. — P. 141−150.
- Mansbach R.S., Brooks E.W., Sanner M.A., Zorn S.H. Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. // Psychopharmaeology (Berl). 1998. — Vol. 135(2). — P. 194−200.
- McElroy J. F., Stimmel J. J., OT>onnell, J. M.: Discriminative stimulus properties of haloperidol. //DrugDev. Res. 1989. — Vol.18. — P.47−55.
- Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. // Schiz. Bull. 1991. — Vol. 17. -P. 263−287.
- Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsycholic drugs on the basis of dopamine D-l, D-2 and serotonin- pKi values. // J Pharmacol Exp Ther. 1989. — Vol.251. — P.238−246.
- Merchant K. M., Letter A. A., Gibb J. W. Hanson G.R. Changes in the limbic neurotensin systems induced by dopaminergic drugs. // Eur. J. Pharmacol. 1989. — Vol. 153.-P.1−9.
- Merchant K.M., Dobner PR. and Dorsa D.M. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. // J.Neurosci. 1992. — Vol. 12(2). — P.652−663.
- Merchant K.M., Letter A.A., Gibb J.W., Hanson G.R. Changes in the limbic neurotensin systems induced dy dopaminergic drugs. // Eur. J. Pharmacol. 1988. — Vol. 153. -P.l-9.
- Merchant K.M., Miller MJL, Ashleigh EJL and Dorsa D.M. Haloperidol rapidly increases the number of neurotensin mRNA-expressing neurons in neostriatum of the rat brain. //Brain Research. -1991. Vol. 540. -P.311−314.
- Miller L.G., Jankovic J. Sulpiride-induced tardive dystonia. // Mov. Disord. -1990.-Vol. 5(1).-P. 83−84.
- Miroshnichenko I.I., Kudrin V.S., Raevskii K.S. Effect of carbidine, sulpiride and haloperidol on levels of monoamines and their metabolites in the brain structures of rats., // Farmakol Toksikol. 1988. — Vol.51(2). — P.26−29.
- Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. // Cell. 1999. -Vol.98. — P.427−436.
- Moore NA, Calligaro DO, Wong DT, et al. The pharmacology of olanzapine and other new antipsychotic agents. // Curr. Opin. Inv. Drugs. 1993. — Vol.2. — P.281−293.
- Morelli M., Di Choara G. Catalepsy induced by SCH23390 in rats. // Eur.J.Pharmacol. 1985. — Vol.117(2). — P. 179−185.
- Morpurgo C. Effects of antiparkinson drugs on a phenothiazine-induced catatonic reaction. //Arch. Int. Pharmacodyn. 1962. — Vol. 137(1−2). — P.92−96.
- Nemeroff C. B., Bissette G., Prange A. J. Jr., Loosen P. T., Barlow T. S. and Lipton M. A. Neurotensin: central neurous system effects of a hypothalamic peptide. // Brain Res. 1977. — Vol.128. — P.485−496.
- Nemeroff C. B., Hernandez D. E., Luttinger D., Kalivas P. W., Prange A. J., Jr. Neurotensin, a Brain and Gastrointestinal Peptide (C. B. Nemeroff and A. J. Prange, Jr., eds.) // The New York Academy Sciences, New York. 1982. — P. 330−344.
- Nemeroff C.B. Neurotensin: Perchance an endogenous neuroleptic? // Biol.Psychiatry. 1980. — Vol.15. — P.283−302.
- Nielsen E. B. Regulation of drug discrimination behaviour by dopamine Di and D2 receptors. // In D1: D2 Dopamine Receptor Interactions, /ed. by J. Waddington / Academic Press, London, 1993, P. 159−173.
- Niemegeers C. J. E., Verbruggen F. J., Janssen P. A. J. The influence of various neuroleptic drugs on shock avoidance responding in rats. // Psychopharmacology. -1969. -Vol. 16. -P. 161−174.
- Nieollon A., Krekerian L., Duticier N. Presynaptic controls in the neostriatum: reciprocal interactions between the nigro-striatal dopaminergic neurons and the cortico-striatal glutamatergic pathway. //Exp.Brain. Res. 1983. — Suppl.7. — P.54−65.
- Overton D. A.: State-dependent learning produced by depressant and atropine-like drugs. // Psychopharmacologia (Beri.). 1966. — Vol.10. — P.6−31.
- Overton D.A. State dependent learning and. drug discrimination. // In: Handbook of Psychopharmacology. 1984. — Vol.18. — P.59−112.
- Palacios J. M., Kuhar M. J. Neurotensin receptors are located on dopamine-containing neurones in rat midbrain. //Nature. -1981. Vol.294. P.587−589.
- Panteleeva G. P., Tsutsulkovskaya M. Y., Belyaev B. S., Minsker E. I. Clozapine in the treatment of schizophrenic patients: an international multicenter trial. // Clin. Therapentics. 1987. -Vol. 10.-P. 57−68.
- Parashos S.A., Marin C., Chase T.N. Synergy between a selective D1 antagonist and a selective D2 antagonist in the induction of catalepsy. // Neurosci. Lett. -1989, — Vol. 105.-P. 169−173.
- Phillips G., Willner P., Muscat R. Neuroleptic inducted response decrement in the absence of effects on reward. //Psychopharmacology.-1990. -Vol. 101. Suppl. -P. 43.
- Piercey M. F., Lum J. T. Electrophysiological effects of dopamine autoreceptor antagonists, (+) AJ-76 and (+) UH-232. // Eur. J. Pharmacol., -1990. Vol. 182. N. 2−3. -P. 219−226.
- Pilotte N.S., Mitche U M., Sharpe L.G., DeSouza E.B. and Dax E.M. Chronic cocaine administration and withdrawal of cocaine modify neurotensin binding in rat brain. // Synapse. -1991. Vol. 9. — P. lll-120.
- Polk D.L., Lipton J.M. Effects of sodium salicylate, aminopyrine and chlorpromazine on behavioral temperature regulation. // Pharmacol. Biochem. Behav. -1975. -Vol.3(2).-P. 167−172.
- Porsolt R.D. Animal model of depression. //Biomedicine. 1979. — Vol.30(3). -P. 139−140
- Protais P., Costentin J., Schwartz J.C. Climbing behavior indused by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. // Psychopharmacol. 1976. — Vol.50. — P. 1−6.
- Protais P., Hermier C., Costentin J. The discriminant dopamine antagonist property of benzamides is observed at various times after their administration. // Neuropharmacology. -1985. -Vol. 24.-P. 861−867.
- Quirion R., Gaudreau P., St.-PierTe S., Rioux F. and Pert C. B. Autoradiographic distribution of 3H. neurotensin receptors in rat brain: visualization by tritium-sensitive Film. //Peptides. 1982. — Vol.3(5). — P.757−763.
- Quirion R., Regoli D., Rioux F. and St.-Pierre S. The stimulatory effects of neurotensin and related peptides in rat stomach strips and guinea-pig atria. // Br. J. Pharmacol. 1980. — Vol.68(l). — P.83−91.
- Rakovska A., Giovannini M.G., Delia Corte L., Kalfin R., Bianchi L., Pepeu G. Neurotensin modulation of acetylcholine and GAB A release from the rat hippocampus: an in vivo microdialysis study. // Neurochem Int. 1998. — Vol.33(4). — P.335−340.
- Rathbun R.C., Slater J.H. Amitriptyline and nortriptyline as antagonists of central and periferal cholinergic activation. // Psychopharmacology. 1963. — Bd40(4). -S.lll-125.
- Reavill C., Kettle A., Holland V., Riley G., Blackburn T.P. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. // Br. J. Pharmacol. -1999. Vol. 126(3). — P.572−574.
- Redolat R., Brain P. F., Simon V. M. Sulpiride has an antiaggressive effect in mice without markedly depressing motor activity. // Neuropharmacology. -1991. -Vol. 30. -N. I. -P. 41−46.
- Reynolds G.P. and Mason S.L. Are striatal dopamine D4 receptors increased in schizophrenia? //J. Neurochemistry. 1994. — Vol. 63. — P. 1576−1577.
- Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. // J.Clin. Psychiatry. 1996. — Vol.57(suppl.ll). — P.4−11.
- Rivier J. E., Lazarus L. H., Peirin M. H. and Brown M. R. Neurotensin analogues. Structure-activity relationship. //J. Med. Chem. 1977. — Vol.20(ll). — P. 14 091 412.
- Roufogalis B. D., Thornton M. and Wade D. N. Specificity of the dopamine sensitive adenilate cyclase for antipsychotic antagonists. // Life Sci. 1976. — Vol. 19(6). -P. 927−934.
- Rupniak N.M., Hall M.D., Mann S., Fleminger S., Kilpatrick G., Jenner P., Marsden C.D. Chronic treatment with clozapine, unlike haloperidol, does not induce changes. //Biochem Pharmacol. 1985. — Vol.34(15). — P.2755−2763.
- Sailer CF, Salama Al. Seroquel: biochemical profile of a potential atypical antipsychotic. //Psychopharmacology (Berl). 1993. -Vol.112. — P.285−292.
- Salmi P., Karlsson T., Ahlenius S. Antagonism by SCH 23 390 of clozapine-induced hypothermia in the rat. //Eur. J. Pharmacol. 1994. — Vol. 253 (1−2). — P.67−73.
- Sanger D. J. The effects of ciozapine on shuttle-box avoidance responding in rats: comparisons with haloperidol and chlordiazepoxide. // Pharmacol. Biochem. Behav. -1985. -Vol. 23.-P. 231−236.
- Sanger D.J., Perrault G. Effects of typical and atypical antipsychotic drugs on response decrement. II J. Pharmacol. Exp. Ther. 1995. — Vol.272(2). — P.708−713.
- Sanger, D. J., Perrault, G.H., Schoemaker H., Scatton B. The pharma-cological properties oftiapride. //Biblio. Psychiatrica. 1997. — Vol.167. — P.241−243.
- Sanz B., Exposito I., Mora F., Effects of neurotensin on the release of glutamic acid in the prefrontal cortex and striatum of the rat. // Neurorept. 1993. — Vol.4(10). -P.l 194−1196.
- Sarhan S., Hitchcock J.M., Grauffel C.A., Wettstein J.G. Comparative antipsychotic profile of meurotensin and a related systemically active peptide agonist. // Peptides. 1997. — Vol. 18(8). — P. 1223−1227.
- Scatton B., Claustre Y., Cudennec A., Oblin A., Perrault G., Sanger D.J., Schoemaker H. Amisulpride: from animal pharmacology to therapeutic action. // Int. Clin. Psychopharmacol. 1997. — Vol.12. — Suppl 2. — S29−36.
- See R. E., Ellison G. Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardiave dyskinesia. //Eur. J. Pharmacol. -1990. -Vol. 181. -P. 175−186.
- Seeman P. and Van Tol H.H.M. Dopamine receptor pharmacology. // Trends Pharmacol. Sci. 1994. — Vol. 15. — P. 264−270.
- Seeman P., Lee T., Chau-Wong, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. // Nature. 1976. — Vol.261. — P.717−719.
- Seiden L.S., Martin T.W.Jr. Potentiation of effects of L-DOPA on conditioned aviodance behavior by inhibition of extracerebral dopa decarboxylase. // Physiol.Behav. -1971. Vol.6(4). — P.453−458.
- Seiden L.S., Sabol K.E., Ricaurte G.A. Amphetamine: effects on catecholamine systems and behavior. // Ann. Rev. Pharmacol. Toxicol. 1993. — Vol.32. -P.639−677.
- Setyonegoro R. K., Kamadi J., Darmabrata W. Clinical trial of clozapine (leponex. Sandoz) on Indonesian Schizophrenic patients. // Jiwa Indonesian Psychiatric Quarterly. -1975. -Vol. 8. -P. 61−71.
- Sigala S., Missale C., Spano P. Opposite effects of dopamine D2 and D3 receptors on learning and memoiy in the rat. // Eur. J. Pharmacol. 1997. — Vol.336(2−3). -P. 107−112.
- Singh N.A., Bush L.G., Gibb J.W., Hanson G.R. Dopamine-mediated changes in central nervous system neurotensin systems: a role for NMDA receptors. // Eur. J. Pharmacol. 1990. — Vol. 187. — P.337−344.
- Singh NJL, Bush L.G., Gibb J.W. and Hanson G.R. Role of N-methyl-D-aspartate receptors in dopamine Dl5 but not D2, mediated changes in. striatal and accumbens neurotensin systems. // Brain Research. 1992. — Vol. 571. — P.260−264.
- Skarsfeldt T. Pharmacology of sertindole, a novel atypical neuroleptic. // New Generation of Antipsychotic Drugs: Novel Mechanisms of Action 1993. — Vol.4. — P.62−66.
- Skuza G., Rogoz Z., Wieczorek A. Neuropsychopharmacological profile of remoxipride in comparison with clozapine. // Pol. J. Pharmacol. 1997. — Vol.49(l). — P.5−15
- Snider R.M., Pereira D.A., Longo K.P., Davidson R.E., Vinick F.J., Laitinen K., Genc-Sehitoglu E., Crawley J.N. // Bioorg.Med.Chem.Lett. 1992. — Vol.2. — P. 15 351 540.
- Snijders R., Kramarcy N. R., Hurd R. W., Nemeroff C. B. and Dunn A. J. Neurotensin induced catalepsy in mice. // Neuropharmacology. 1982. — Vol.21. — P.465−468.
- Sokoloff P., Giros B., Martres M.-P., Bouthenet M.-L., Schwartz J.-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. // Nature. 1990. — Vol. 347. — P. 146−151.
- Sommer S.S., Lind T.J., Heston L.L., et al. Dopamine-D (4) receptor variants in unrelated schizophrenic cases and controls. // Am. J. Med. Genet. 1993. — Vol.48. — P. 9093.
- Souto M., Montim J. M., Altier H. Effects of clozapine on the activity of central dopaminergic and noradrenergic neurons. // Pharmacol. Biochem. Behav. -1979. -Vol. 10. -P. 5−9.
- Srivastava A.K., Srivastava Y.P., Gupta P.P., Verma R.B. Characterization of dopamine receptors involved in central thermoregulation in rabbits. // Indian. J. Exp. Biol. 1991. — Vol.29(ll). — P. 1087−1088.
- Stahle L, Ungerstedt U. Effects of neuroleptic drugs on the inhibition of exploratory behaviour induced by low dose of apomorphine: implications for the identity of dopamine receptors. //Pharmacol. Biochem. Behav. -1986. -Vol. 25. P. 473−480.
- Stanley B. G., Eppel N, Hoebel B. G. Neurotensin, a Brain and Gastrointestinal Peptide (C. B. Nemeroff and A. J. Prange, Jr., eds.) // The New York Academy Sciences, New York. 1982. — P. 425−427.
- Stanley M. and Wilk S. Striatal DOPAC evaluation predicts antipsychotic efficacy of metoclopramide. //Life Sci. 1979. — Vol.24(20). — P. 1907−1922.
- Stewart J. Differential responses based on the physiological consequences of pharmacological agents. //Psychopharmacologia. 1962. — Vol.3. — P. 132−138.
- Strange P.G. Interesting times for dopamine receptors. // Trends Neurosci. -1991. Vol.14. -P.43−45.
- Suarez-Roca H., Lovenberg L, Cubeddu L. X. Comparative dopami-ne-cholinergic mechanisms in the olfactory tubercle and the striatum: effects of metaclopramide. //J. Pharmacol. Exp. Ther. -1987,-Vol. 243. -P. 840−851.
- Tamminga C. A., Gerlach J., New neuroleptics and experimental antipsychotics in schizophrenia. // Psychopharmacology: the third generation of progress. (Eds. H. Y. Meltzer) -New York. -Raven Press. -1987. -P. 1129−1138.
- Tremblay M, Rouillard C, Levesque D. The antisense strategy applied to the study of dopamine D3 receptor functions in rat forebrain. // Neurosci. 1998. — Vol. 86(3). -P.799−811.
- Tsuchiya Y., Sasaki A., Yoshino H., Karibe N., Sugimoto H., Kubota A., Kosasa M., Araki S., Ikeda M., Yamanishi Y., Machida R., Yamatsu K. // EPA 89 104 302.8. 1989.
- Van Tol H.H.M., Bunzow J R., Guan H.C. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. // Nature. 1991. -Vol.350.-P. 610−614.
- Van Tol H. H. M., Wu C. M., Guan H. Ch., Ohara K., Bunzow J. R., Civelli 0., Kennedy J., Seeman Ph., Niznic H., Jovanovic V. Multiple dopamine-D4 receptor variants in the human population. // Nature. 1992. — Vol. 358. — P. 149−152.
- Watson C.B., Watson A.W., Murray KLD., Isackson P. J., Richelson E. Haloperidol but not clozapine increases neurotensin receptor mRNA levels in rat substantia niora. // J. Neurochem. 1993. — Vol.61. — P. 1141 -1143.
- Westerink B. H. C. Neurobiology of Dopamine /A. S. Horn, J. Kolfmd B. H. C.- Westerink, eds. Academic Press, London. — 1979. — P. 255−273.
- Willner P., Sampson D., Phillips G., Muscat R. A matching law analysis of the effects of dopamine receptor antagonists. // Psychopharmacology. -1990. -Vol. 101. -N. 4. -P. 560−567.
- Winter C.A. The potentiating effect of antihistaminic drugs upon the sedative action of barbiturates. // J.Pharmacol. Exp. Ther. 1948. — Vol.94. — P.7−11.
- Wise L.D., Wustrow D.J. Neurotensin mimetics as central nervous system agents. // US 5,407,916. 1995.
- Woolfe G., Macdonald A.D. The evaluation of the analgesic action of pethidine hydrochloride (Demerol). // J. Pharmacol. Exp. Ther. 1944. — Vol.80. — P.300−307.137
- Yaksh T. L., Schmauss C., Miceviych P. E., Abay E. O. and Go V. L. W. Neurotensin, a Brain and Gastrointestinal Peptide /C. B. Nemeroff and A. J. Prange Jr., eds. The New York Academy of Sciences, New York — 1982. — P. 228−243.
- Yamada M., Yamada M., Lombet A., Forgez P., Rostene W. Distinct functional characteristics of levocabastine sensitive rat neurotensin NT2 receptor expressed in Chinese hamster ovary cells. II Life. Sci. 1998. — Vol.62(23). — PL 375−380.
- Yamada M., Yamada M., Richelson E. Further characterization of neurotensin receptor desensitization and down-regulation in clone N IE-115 neuroblastoma cells. // Biochem. Pharmacol. 1993. — Vol.45. — P.2149−2154.
- Young R., Glennon R. A. Discriminative stimulus properties of amphetamine and structurally related phenalkylamines. // Med. Res. Rev. 1986. — Vol.6. — P.99−130.
- Zarrindast M. R., Habibi-Moini S. Blockade of both D-l and D-2 dopamine receptors may induce catalepsy in mice. // Gen. Pharmacol. -1991. -Vol. 22. -N. 6. -P. 1023−1026.
- Zarrindast M. R., Minaian A. Different effects of direct and indirect dopamine receptor agonists on immobility time in reserpine treated mice. // Gen. Pharmacol. -1991. -Vol. 22. -N. 6. -P. 1017−1021.
- Zarrindast M.R., Tabatabai S.A. Involvement of dopamine receptor subtypes in mouse thermoregulation. // Psychopharmacology (Berl). 1992. — Vol. 107(2−3). — P.341−346.
- Zeng X.P., Le F., Scarisbrick I. Muscarinic m4 receptor agonism by atypical but not typical antipsychotics. // Soc. Neurosci. Abstracts. 1995. — Vol.21. — P. 1707.
- Zom S.H., Jones S.B., Ward K.M. Clozapine is potent and selective muscarinic M (4) receptors agonist. // Eur. J. Pharmacol. 1994. — Vol.269. — P. R1-R2.